Ariad Pharmaceuticals Inc. was a big mover last session, as the company saw its shares rise almost 8% on the day. The upside was driven by the initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed for patients with non-small cell lung cancer (NSCLC). This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 21% in the past one-month time frame.

Over the last 30 days, the company witnessed four positive estimate revisions and the Zacks Consensus Estimate moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

Ariad Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked med-drugs stock is Juniper Pharmaceuticals, Inc. which sports a Zacks Rank #1 (Strong Buy).

Is ARIA going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>